SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Springworks Therapeutics (SWTX – Research ...
AITX Artificial Intelligence Technology Solutions Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback